🇺🇸 FDA
Pipeline program

TD-1473 Dose A

0164

Phase 3 small_molecule terminated

Quick answer

TD-1473 Dose A for Ulcerative Colitis (UC) is a Phase 3 program (small_molecule) at Theravance Biopharma with 2 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Ulcerative Colitis (UC)
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials